Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 5, 2009
Wed, February 4, 2009 NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
BEDMINSTER, N.J.--([ BUSINESS WIRE ])--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the 11th Annual BIO CEO and Investor Conference in New York on Tuesday, February 10, 2009 at 11:30 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the NPS website at [ http://www.npsp.com ].
About NPS Pharmaceuticals
NPS Pharmaceuticals is developing therapeutics for rare gastrointestinal and endocrine disorders with high-unmet medical needs. The company is currently advancing two late-stage programs. Teduglutide, a proprietary analog of glucagon-like peptide-2, is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome as GATTEX™ and in preclinical development for additional intestinal failure related conditions. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 3 clinical development as a hormone therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Kirin, Ortho-McNeil, and Nycomed. Additional information is available at [ http://www.npsp.com ].
